Olmesartan medoxomil treatment potently improves cardiac myosin-induced dilated cardiomyopathy via the modulation of ACE-2 and ANG 1-7 mas receptor.

Sukumaran, Vijayakumar

Olmesartan medoxomil treatment potently improves cardiac myosin-induced dilated cardiomyopathy via the modulation of ACE-2 and ANG 1-7 mas receptor. [electronic resource] - Free radical research Jul 2012 - 850-60 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1029-2470

10.3109/10715762.2012.684878 doi


Angiotensin I--metabolism
Angiotensin II Type 1 Receptor Blockers--administration & dosage
Angiotensin-Converting Enzyme 2
Animals
Biomarkers--metabolism
Cardiac Myosins--administration & dosage
Cardiomyopathy, Dilated--chemically induced
Endopeptidases--metabolism
Fibrosis--prevention & control
Gene Expression Regulation--drug effects
Heart--drug effects
Hypertrophy, Left Ventricular--prevention & control
Imidazoles--administration & dosage
Mitogen-Activated Protein Kinases--antagonists & inhibitors
Olmesartan Medoxomil
Peptide Fragments--metabolism
Peptidyl-Dipeptidase A--genetics
Proto-Oncogene Mas
Proto-Oncogene Proteins--antagonists & inhibitors
RNA, Messenger--biosynthesis
Rats
Receptors, G-Protein-Coupled--antagonists & inhibitors
Tetrazoles--administration & dosage